FY2027 EPS Estimates for McKesson Lowered by Leerink Partnrs

McKesson Co. (NYSE:MCK) – Leerink Partnrs decreased their FY2027 EPS estimates for shares of McKesson in a research note issued to investors on Wednesday, April 2nd. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $41.75 per share for the year, down from their previous estimate of $41.98. The consensus estimate for McKesson’s current full-year earnings is $32.77 per share. Leerink Partnrs also issued estimates for McKesson’s FY2027 earnings at $41.75 EPS.

Several other equities research analysts have also issued reports on the company. Bank of America reduced their price target on McKesson from $680.00 to $650.00 and set a “buy” rating for the company in a report on Monday, January 6th. Mizuho lifted their target price on shares of McKesson from $630.00 to $690.00 and gave the company a “neutral” rating in a research note on Thursday. Morgan Stanley increased their price target on shares of McKesson from $642.00 to $745.00 and gave the stock an “overweight” rating in a research note on Wednesday. Evercore ISI lifted their price objective on shares of McKesson from $650.00 to $675.00 and gave the company an “outperform” rating in a research note on Thursday, February 6th. Finally, Citigroup decreased their price objective on shares of McKesson from $713.00 to $677.00 and set a “buy” rating for the company in a report on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, McKesson currently has an average rating of “Moderate Buy” and an average target price of $661.00.

McKesson Price Performance

Shares of NYSE MCK opened at $716.71 on Friday. McKesson has a one year low of $464.42 and a one year high of $758.64. The business’s 50-day moving average price is $631.55 and its two-hundred day moving average price is $583.78. The company has a market capitalization of $89.82 billion, a P/E ratio of 32.82, a price-to-earnings-growth ratio of 1.29 and a beta of 0.49.

McKesson (NYSE:MCK) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $8.03 EPS for the quarter, missing the consensus estimate of $8.60 by ($0.57). McKesson had a net margin of 0.82% and a negative return on equity of 181.26%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in McKesson during the fourth quarter worth about $1,200,361,000. Farallon Capital Management LLC acquired a new stake in shares of McKesson during the 4th quarter worth approximately $348,044,000. Marshall Wace LLP increased its position in shares of McKesson by 59,720.3% during the fourth quarter. Marshall Wace LLP now owns 358,922 shares of the company’s stock valued at $204,553,000 after purchasing an additional 358,322 shares during the period. Leigh Baldwin & CO. LLC acquired a new position in shares of McKesson in the fourth quarter valued at $182,861,000. Finally, Proficio Capital Partners LLC acquired a new position in shares of McKesson in the fourth quarter valued at $178,397,000. Institutional investors and hedge funds own 85.07% of the company’s stock.

Insider Activity at McKesson

In other news, EVP Leann B. Smith sold 188 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $609.59, for a total transaction of $114,602.92. Following the completion of the transaction, the executive vice president now directly owns 1,051 shares in the company, valued at $640,679.09. The trade was a 15.17 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Brian S. Tyler sold 8,961 shares of the firm’s stock in a transaction on Friday, February 21st. The stock was sold at an average price of $597.99, for a total transaction of $5,358,588.39. Following the completion of the sale, the chief executive officer now owns 60,664 shares in the company, valued at approximately $36,276,465.36. The trade was a 12.87 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 18,110 shares of company stock worth $10,855,706 in the last 90 days. 0.11% of the stock is owned by company insiders.

McKesson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 1st. Investors of record on Monday, March 3rd were given a dividend of $0.71 per share. The ex-dividend date of this dividend was Monday, March 3rd. This represents a $2.84 annualized dividend and a dividend yield of 0.40%. McKesson’s dividend payout ratio is presently 13.00%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.